最新一期业绩显示，2025年一季报，公司实现营业收入5.50亿元，同比28.80%；净利润1.03亿元，同比 67.04%，销售毛利率69.64%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)80大博医疗39.6244.214.94157.74亿行业平均 51.0048.824.68108.70亿行业中值37.0337.302.5049.80亿1天益医疗-1801.27-3085.371.9222.95亿2澳华内 镜-688.49345.315.5272.56亿3诺唯赞-425.24-502.942.3391.00亿4爱朋医疗-416.91316.735.0234.21亿5博晖 创新-341.86542.483.6550.16亿6奥精医疗-150.60-220.731.9927.95亿7硕世生物-144.86-2116.821.3042.37亿 8睿昂基因-104.65-85.921.4813.55亿9康泰医学-87.91-74.273.1457.86亿10中红医疗-73.24-58.410.9350.90亿 11热景生物-66.56-76.694.91146.48亿 来源：金融界 6月10日，大 ...

最新一期业绩显示，2025年一季报，公司实现营业收入5.50亿元，同比28.80%；净利润1.03亿元，同比 67.04%，销售毛利率69.64%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)81大博医疗39.1843.724.88156.00亿行业平均 48.9247.334.59105.60亿行业中值35.6837.002.4048.12亿1天益医疗-1741.60-2983.161.8622.19亿2澳华内 镜-632.39317.185.0766.65亿3诺唯赞-396.61-469.092.1884.88亿4爱朋医疗-353.16268.304.2528.98亿5博晖 创新-319.03506.263.4046.81亿6硕世生物-133.10-1944.971.1938.93亿7奥精医疗-129.86-190.331.7124.10亿 8睿昂基因-100.04-82.131.4212.95亿9康泰医学-85.53-72.263.0556.29亿10中红医疗-70.71-56.400.8949.14亿 11华大智造-57.49-51.023.96306.51亿 资金流向方面，5月26日，大 ...

Group 1 - The core stock price of Dabo Medical (002901) closed at 38.11 yuan on May 23, 2025, reflecting a 0.4% increase from the previous week's closing price of 37.96 yuan [1] - The highest intraday price reached 39.09 yuan on May 19, 2025, while the lowest intraday price was 37.56 yuan on May 22, 2025 [1] - The current total market capitalization of Dabo Medical is 15.778 billion yuan, ranking 12th out of 126 in the medical device sector and 960th out of 5148 in the A-share market [1] Group 2 - Dabo Medical held its 2024 annual general meeting on May 21, 2025, with a total of 7 shareholders and representatives present, representing 347,095,811 shares, which is 83.8356% of the total shares [2] - An additional 87 shareholders participated via online voting, representing 3,634,395 shares, or 0.8778% of the total shares [2] - The meeting approved several resolutions, including the 2024 annual financial report and the proposal for the distribution of profits [2] Group 3 - The profit distribution plan for 2024 states that Dabo Medical will distribute a cash dividend of 5.00 yuan (including tax) for every 10 shares, totaling 203.304803 million yuan (including tax) [3] - The record date for the distribution of rights is set for May 29, 2025, and the ex-dividend date is May 30, 2025 [3] - No bonus shares will be issued, and there will be no capital reserve fund conversion into share capital [3]

证券代码：002901 证券简称：大博医疗 公告编号：2025-027 大博医疗科技股份有限公司 2024 年年度利润分配实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、大博医疗科技股份有限公司（以下简称"公司"）回购专用证券账户中 的股份 7,409,900 股不参与本次利润分配。公司 2024 年年度利润分配方案为：以 公司总股本 414,019,506 股扣除公司回购专用证券账户中的 7,409,900 股后的 406,609,606 股为基数，向全体股东每 10 股派发现金股利 5.00 元（含税），合计 派发现金红利 203,304,803.00 元（含税），不送红股，不以资本公积金转增股本。 如公司总股本在分配预案披露至实施期间因可转债转股、股份回购、股权激励行 权、再融资新增股份上市等原因而发生变化的，将按照分配比例不变的原则对分 配总额进行调整。 2、本次实施利润分配后，按公司总股本（含回购股份）折算每股现金分红 计算如下：按总股本折算每 10 股现金红利=现金分红总额÷公司总股本（含回购 股份）×10=203,304 ...

Core Viewpoint - The legal opinion letter issued by Fujian Xinshi Law Firm confirms that the 2024 Annual General Meeting of Dahua Medical Technology Co., Ltd. is convened and conducted in compliance with relevant laws and regulations, ensuring the legality and validity of the meeting and its resolutions [1][13]. Group 1: Meeting Procedures - The meeting is scheduled for May 21, 2025, and the notice was published on April 24, 2025, on the designated information disclosure website [3][4]. - The meeting will utilize both on-site and online voting platforms, with specific time slots for each voting method [3][4]. Group 2: Attendance and Voting - A total of 7 shareholders attended the meeting, representing 347,095,811 shares, which accounts for 83.8356% of the total shares [4]. - The voting results for various proposals were reported, with significant support from shareholders, including small investors [8][9][10][11][12]. Group 3: Resolutions Passed - The following proposals were approved during the meeting: - 2024 Annual Board Work Report: 350,566,792 shares in favor, representing 84.6740% [7]. - 2024 Annual Supervisory Board Work Report: 350,566,792 shares in favor, representing 84.6740% [9]. - 2024 Annual Financial Settlement Report: 350,565,792 shares in favor, representing 84.6737% [10]. - 2024 Profit Distribution Proposal: 350,720,906 shares in favor, representing 84.7112% [11]. - 2024 Annual Report: 350,566,292 shares in favor, representing 84.6739% [12]. - Appointment of 2025 Audit Firm: 350,411,006 shares in favor, representing 84.6364% [12]. - 2025 Executive Compensation Assessment Method: 350,722,306 shares in favor, representing 84.7115% [12].

证券代码：002901 证券简称：大博医疗 公告编号：2025-026 大博医疗科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议的召开和出席情况 （一）会议召开情况 1、会议召开的日期、时间： （1）现场会议召开时间：2025 年 5 月 21 日（星期三）下午 14:00 （2）网络投票时间： ①通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 21 日 上午 9:15-9:25、9:30-11:30，下午 13:00-15:00。 ②通过深圳证券交易所互联网投票系统投票的开始时间为 2025 年 5 月 21 日 上午 9:15 至下午 15:00 期间的任意时间。 2、会议召开方式：本次股东大会采用现场表决与网络投票相结合的方式召 开。 3、会议召集人：公司董事会 4、会议主持人：公司董事长林志雄先生主持会议。 1 5、现场会议地点： 厦门市海沧区山边洪东路 18 号公司 ...

福建信实律师事务所 关于 大博医疗科技股份有限公司 2024 年年度股东大会 之 法 律 意 见 书 福建信实律师事务所 中国·厦门市思明区湖滨南路 334 号二轻大厦 9 层 电话/Tel：86 592 590 9988 传真/Fax：86 592 590 9989 www.lhxs.com 厦门湖滨南路 334 号二轻大厦 9 楼 邮编 361001 电话 +86 592 5909988 传真 +86 592-5909989 www.lhxs.com 福建信实律师事务所 关于大博医疗科技股份有限公司 2024 年年度股东大会之 法 律 意 见 书 (2025)闽信实律书字 0135 号 致：大博医疗科技股份有限公司 福建信实律师事务所(以下简称"本所")受大博医疗科技股份有限公司(以下 简称"公司")的委托，指派许智明律师、吴上烁律师 (以下简称"本所律师") 出席公司于2025年5月21日召开的公司2024年年度股东大会(以下简称"本次股东 大会")。本所律师根据《中华人民共和国公司法》(以下简称"《公司法》")、《中 华人民共和国证券法》(以下简称"《证券法》")、《上市公司股东会规则》(以下 简称" ...

Core Viewpoint - Dabo Medical's stock closed at 38.44 yuan, down 2.04%, with a rolling PE ratio of 39.97 times and a total market value of 15.915 billion yuan [1] Company Summary - Dabo Medical Technology Co., Ltd. specializes in the production, research, and sales of high-value medical consumables, including intramedullary nails, hollow nails, ordinary plates, locking plates, and various orthopedic products [1] - The latest quarterly report for Q1 2025 shows that the company achieved operating revenue of 550 million yuan, a year-on-year increase of 28.80%, and a net profit of 103 million yuan, a year-on-year increase of 67.04%, with a gross profit margin of 69.64% [1] Shareholder Information - As of March 31, 2025, Dabo Medical had 18,310 shareholders, an increase of 374 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Summary - The average PE ratio for the medical device industry is 49.84 times, with a median of 36.59 times, placing Dabo Medical at the 81st position in the industry ranking [2] - The industry average market value is 105.51 billion yuan, while the median market value is 46.93 billion yuan [2]

Core Viewpoint - The company has emerged from the impact of centralized procurement, achieving strong growth in its traditional orthopedic segment on a low base, and successfully expanding into new business areas, maintaining a buy rating [1] Investment Highlights - The company maintains a buy rating, with projected EPS for 2025-2026 at 1.24/1.64 yuan, and a new EPS forecast for 2027 at 1.99 yuan. The target PE for 2025 is set at 36X, with an updated target price of 44.64 yuan (previously 42.65 yuan) [2] - In 2024, the company achieved revenue of 2.136 billion yuan (up 39.3% YoY) and a net profit attributable to shareholders of 357 million yuan (up 505%). The non-recurring net profit was 285 million yuan (up 2604%) [2] - In Q1 2025, the company reported revenue of 550 million yuan (up 28.8% YoY) and a net profit of 103 million yuan (up 67%), with non-recurring net profit at 97 million yuan (up 97%) [2] - The performance in 2023 was affected by inventory adjustments due to centralized procurement in 2021 and 2022, leading to a low base for 2024, which is expected to see continued growth as the impact clears [2] Orthopedic Product Lines - The core orthopedic product lines have recovered from the impact of centralized procurement, with trauma and spinal product lines showing continuous sales growth. In 2024, trauma product sales are expected to reach 821 million yuan (up 43.4%), with a gross margin increase of 3.67 percentage points to 75.34% [3] - Spinal product revenue in 2024 is projected at 388 million yuan (up 36.9%), with a slight decline in gross margin by 1.06 percentage points to 67.66% due to high prices before centralized procurement [3] - Joint products are also expected to maintain good growth, with projected revenue of 189 million yuan (up 21.1%) in 2024 [3] Non-Orthopedic Consumables - The non-orthopedic consumables business is showing good growth potential, aiming to contribute to a second growth curve for the company. In 2024, R&D investment is expected to reach 307 million yuan, accounting for 14.4% of revenue [4] - Minimally invasive surgical products are projected to achieve revenue of 363 million yuan (up 26.5%) with a gross margin increase of 1.77 percentage points to 78.19% [4] - Revenue from neurosurgical products is expected to be 103 million yuan (up 26.3%), dental products at 67 million yuan (up 28.2%), and other products at 162 million yuan (up 141%) [4]

Investment Rating - The report initiates coverage with an "Outperform" rating for the company [4][13]. Core Views - The company has emerged from the impact of centralized procurement, achieving strong growth on a low base in its traditional orthopedic segment, and successfully expanding into new business areas [1][5]. - The forecasted EPS for 2025-2026 is RMB 1.24 and RMB 1.64, with a new forecast for 2027 at RMB 1.99. A target PE of 36X for 2025 is set, leading to a target price of RMB 44.64 [5][13]. Financial Summary - In 2024, the company is expected to achieve revenue of RMB 2.14 billion, a year-on-year increase of 39.3%, and a net profit attributable to shareholders of RMB 357 million, reflecting a 505% increase [5][14]. - For Q1 2025, revenue is projected at RMB 550 million, up 28.8%, with a net profit of RMB 103 million, an increase of 67% [5][14]. - The company’s revenue growth is attributed to the clearing of inventory adjustments from previous centralized procurement impacts, leading to a strong performance in 2024 [5][14]. Business Segments - The core orthopedic product lines, including trauma and spine products, have shown continued sales growth post-centralized procurement, with trauma sales revenue in 2024 expected to reach RMB 821 million, a 43.4% increase [5][15]. - Non-orthopedic consumables are also experiencing good growth, with the company aiming to become a medical equipment platform, investing heavily in R&D [5][16].